[Pharmacological therapeutic intervention in mild cognitive impairment]

Area of Science:

• Neurology
• Gerontology
• Pharmacology

Background:

• Mild cognitive impairment (MCI) is a heterogeneous syndrome with varied causes, including degenerative, vascular, and psychiatric factors.
• MCI presents with diverse affective, behavioral symptoms, and clinical courses, necessitating individualized treatment approaches.

Purpose of the Study:

• To describe preventive and therapeutic pharmacological interventions for Mild Cognitive Impairment (MCI).
• To highlight the importance of combining pharmacological treatments with non-pharmacological measures for managing MCI.

Main Methods:

• Review of pharmacological interventions including vascular risk factor control, avoidance of iatrogeny, and use of specific agents.
• Inclusion of nutraceuticals, CDP-choline, and Ginkgo biloba EGb 761® as therapeutic options.
• Emphasis on improving sensory organ function as a supportive measure.

Main Results:

• Identified key pharmacological agents and strategies for MCI management.
• Demonstrated the necessity of a multimodal approach integrating drug therapies and lifestyle interventions.
• Highlighted the potential benefits of Ginkgo biloba EGb 761® and CDP-choline.

Conclusions:

• MCI requires a multifaceted treatment strategy due to its varied etiology and presentation.
• Pharmacological interventions, including specific supplements and risk factor management, play a crucial role.
• Non-pharmacological approaches and sensory organ improvement are essential complements to medical treatment for MCI.